Trial Search Results
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions in Japanese population by comparing to approved metallic drug eluting stent.
Stanford is currently not accepting patients for this trial.
Abbott Medical Devices
- Device: XIENCE PRIME®/XIENCE Xpedition™
- Device: Absorb™ BVS
1. Subject must be at least 20 years of age.
2. Subject or a legally authorized representative must provide written Informed Consent
prior to any study related procedure, per site requirements.
3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina,
silent ischemia) suitable for elective percutaneous coronary intervention (PCI).
4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
5. Subject must be able to take dual antiplatelet therapy for up to 1 year following the
index procedure and anticoagulants prior/during the index procedure. Therefore the
subject has no known allergic reaction, hypersensitivity or contraindication to
aspirin, clopidogrel, ticlopidine or heparin.
6. Female subject of childbearing potential must not be pregnant* at the index procedure
and does not plan pregnancy for up to 1 year following the index procedure.
* Except for non-pregnancy is apparent, negative pregnancy result within 7 days prior
to the index procedure is required.
7. Female subject is not breast-feeding at the time of the screening visit and will not
be breast-feeding for up to 1 year following the index procedure.
8. Subject agrees to not participate in any other investigational or invasive clinical
study for a period of 13 months following the index procedure
1. Elective surgery is planned within 1 year after the procedure that will require
general anesthesia or discontinuing either aspirin or Thienopyridine.
2. Subject has known hypersensitivity or contraindication to device material and its
degredants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated.
3. Subject has a known contrast sensitivity that cannot be adequately pre-medicated.
4. Subject had an acute myocardial infarction (AMI) within 72 hours of the index
- The subject is currently experiencing clinical symptoms consistent with new onset
AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes
- Creatine Kinase (CK) and Creatine Kinase - Muscle and Brain (CK-MB) have not
returned to within normal limits at the time of index procedure.
5. Subject has an unstable cardiac arrhythmia which is likely to become hemodynamically
unstable due to arrhythmia.
6. Subject has a known left ventricular ejection fraction (LVEF) < 30% (LVEF may be
obtained at the time of the index procedure if the value is unknown and the
investigator believes it is necessary).
7. The target vessel was treated by PCI within 12 months.
8. Prior PCI within the non-target vessel is acceptable if performed anytime > 30 days
before the index procedure or between 24 hours and 30 days before the index procedure
if successful and uncomplicated.
9. Subject requires future staged PCI either in target or non target vessels.
10. Subject has a malignancy that is not in remission.
11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus,
etc.,). Note: corticosteroids are not included as immunosuppressant therapy, diabetes
mellitus is not regarded as autoimmune disease.
12. Subject has received any solid organ transplants or is on a waiting list for any solid
13. Subject has previously received or scheduled to receive radiotherapy to coronary
artery (brachytherapy), or chest/mediastinum.
14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin
or any other agent for any reason).
15. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.
16. Subject has a documented or suspected cirrhosis of Child-Pugh ≥ Class B.
17. Subject has known renal insufficiency;
- Dialysis at the time of screening.
- An estimated Glomerular filtration rate (GFR) < 30 ml/min/1.73m2
18. Subject is high risk of bleeding, or difficult to have appropriate treatment;
- Has a history of bleeding diathesis or coagulopathy
- Has had a significant gastro-intestinal or significant urinary bleed within the
past six months
- Has prior intracranial bleed
- Has prior intracranial bleed (including severe permanent neurologic deficit that
seem to be caused by previous intracranial bleeding)
- Has known intracranial pathology that may cause intracranial bleeding per an
investigator assessment (e.g. untreated aneurysm > 5 mm, arteriovenous
- Subject will refuse blood transfusions
19. Subject has had a cerebrovascular accident or transient ischemic neurological attack
(TIA) within the past six months,
20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
21. Subject has life expectancy < 3 year.
22. Subject is in the opinion of the Investigator or designee, unable to comply with the
requirements of the study protocol or is unsuitable for the study for any reason.
23. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint.
24. Subject whose willingness to volunteer in a clinical investigation could be unduly
influenced by the expectation, whether justified or not, of benefits associated with
participation or of retaliatory response from senior members of a hierarchy in case of
refusal to participate (e.g. subordinate hospital staff or sponsor staff) or subject
is unable to read or write.
Ages Eligible for Study
20 Years - N/A
Genders Eligible for Study